Tivic Health Systems, Inc. (NASDAQ:TIVC) Short Interest Update

Tivic Health Systems, Inc. (NASDAQ:TIVC) was the recipient of a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 62,200 shares, a decline of 23.6% from the September 15th total of 81,400 shares. Approximately 1.0% of the shares of the company are sold short. Based on an average daily volume of 4,950,000 shares, the short-interest ratio is presently 0.0 days.

Tivic Health Systems Price Performance

TIVC stock traded down $0.00 during mid-day trading on Tuesday, reaching $0.23. 187,793 shares of the stock traded hands, compared to its average volume of 1,880,326. Tivic Health Systems has a 52-week low of $0.22 and a 52-week high of $3.21. The stock’s fifty day moving average is $0.30 and its 200-day moving average is $0.53.

Tivic Health Systems (NASDAQ:TIVC) last announced its earnings results on Wednesday, August 14th. The company reported ($0.32) earnings per share for the quarter. The business had revenue of $0.14 million during the quarter. Tivic Health Systems had a negative net margin of 606.47% and a negative return on equity of 172.08%.

Institutional Investors Weigh In On Tivic Health Systems

An institutional investor recently bought a new position in Tivic Health Systems stock. Warberg Asset Management LLC purchased a new position in shares of Tivic Health Systems, Inc. (NASDAQ:TIVC) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 80,000 shares of the company’s stock, valued at approximately $31,000. Warberg Asset Management LLC owned about 1.29% of Tivic Health Systems as of its most recent SEC filing. Institutional investors own 4.25% of the company’s stock.

Tivic Health Systems Company Profile

Tivic Health Systems Inc operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S.